ACB-Form-FCC-Application-Letters-U.S.-Agent-Letter-for-Service-of-Process-Rev01-
tags: Array
(
[0] => Array
(
[url_sha] => 1906b6ef506ba84c4dd8b42a559a2d3d3a590ce607cbb746442da2de62e3e428
[source] => fccid
[url] => https://apps.fcc.gov/eas/GetApplicationAttachment.html?id=6863118
[href_text] => ACB-Form-FCC-Application-Letters-U.S.-Agent-Letter-for-Service-of-Process-Rev01-
[href_description] => EPS Bio Technology Corp. D071 Blood Glucose Monitoring System 2AQBR-D071 2AQBRD071 d071
[http_status] => 200
[http_lastmod] => 0000-00-00 00:00:00
[http_contenttype] => application/pdf
[http_filename] => GetApplicationAttachment.html?id=6863118
[http_size] => 51077
[file_sha256] => 072d5df7451cd760d2ee042fe77ed8ce9d7be6e6d6e9190adc72c76007f337ab
[domain] => document.fccid
)
)
Array
(
[0] => Array
(
[id] => 6863118
[file_sha256] =>
[applicationId] => KlR2g9fe9ctP/XlBTDzsiA==
[description] => ACB-Form-FCC-Application-Letters-U.S.-Agent-Letter-for-Service-of-Process-Rev01-
[shortTermConfidential] => No
[permanentConfidential] => No
[supercede] => No
[exhibitType] => Attestation Statements
[fileType] => Adobe Acrobat PDF
[displayType] => pdf
[fileSize] => 51079
[submissionDate] => 2023-10-18 00:00:00
[dateAvailable] => 2023-10-19 00:00:00
[creationDate] =>
[producer] =>
[modDate] =>
[title] =>
[creator] =>
[author] =>
[pages] =>
[realSize] =>
[html] => 0
[png] => 0
[txt] => 0
[version] => 0
[source] => 0
[fccId] => 2AQBR-D071
[cleanFccId] => 2AQBRD071
[exif] => 0
)
)